This site is designed to provide patients who have been prescribed Blincyto®▼ (blinatumomab) with information about the treatment and other useful materials. Should you have any concerns or questions regarding your treatment with Blincyto®, please speak to your doctor or nurse.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the patient leaflet. Side effects can be reported directly to the Health Products Regulatory Authority (HPRA) using the available methods via Side effects should also be reported to Amgen Limited on +44 (0) 1223 436441 or Freephone 1800 535 160. By reporting side effects you can help provide more information on the safety of this medicine.

Patient Resources

Treatment with BLINCYTO® (blinatumomab) for acute lymphoblastic leukaemia (ALL) - A helpful guide explaining ALL, providing information about Blincyto® and general advice on how to look after yourself. This booklet is intended for Relapsed/Refractory Acute Lymphoblastic Leukaemia patients only.
Educational brochure for patients and caregivers - Important Risk Minimisation Information for Patients and Caregivers
Patient card - for patients to keep it at all times and show to all healthcare providers, so they know the patient is taking Blincyto®.
For a list of possible side effects, please see the patient information leaflet (PIL).

This site is intended for patients in Ireland who are being treated with an Amgen® product and for Irish Healthcare Professionals (HCPs).

I am a member of the public
IE-CBU-0820-00002 August 2020